Toxic Adenoma epidemiology and demographics

Jump to navigation Jump to search

Toxic Adenoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Toxic Adenoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Template:T On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Toxic Adenoma epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Toxic Adenoma epidemiology and demographics

CDC on Toxic Adenoma epidemiology and demographics

Toxic Adenoma epidemiology and demographics in the news

Blogs on Toxic Adenoma epidemiology and demographics

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Toxic Adenoma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]

Overveiw

Epidemiology

Prevalance

  • Toxic adenoma prevalence is inversely related to a population’s dietary iodine sufficiency.

Demographics

Age

  • The incidence of toxic adenoma increases with age; the median age at diagnosis is 50 years.[1]
  • Toxic adenoma is more commonly seen in 56.5% of patients over 60 years but in only 12.5% of the younger patients.

Race

There is no racial predilection to toxic adenoma.

Gender

  • Similar to any thyroid disease females are more commonly affected by toxic adenoma than males.
  • In women and men, the prevalence rate of palpable nodules is 5-7% and 1-2%, respectively.
  • The female-to-male ratio was 14.9:1 for nontoxic AFTNs and 5.9:1 for toxic AFTN patients

References

  1. Hamburger JI (1980). "Evolution of toxicity in solitary nontoxic autonomously functioning thyroid nodules". J. Clin. Endocrinol. Metab. 50 (6): 1089–93. doi:10.1210/jcem-50-6-1089. PMID 7372787.